Biomedical nanotechnology using virus-based nanoparticles

Current Topics in Microbiology and Immunology

Volumn 327, Issue , 2009, Pages 95-122

  Destito, G ^a   Schneemann, A ^b   Manchester, M ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; NANOPARTICLE; VIRUS VACCINE;

BIOMEDICINE; CANCER CELL; COWPEA; FLOCK HOUSE VIRUS; MOSAIC VIRUS; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; VIRUS; VIRUS CAPSID; VIRUS PARTICLE;

ANIMALS; COMOVIRUS; HUMANS; MODELS, MOLECULAR; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NODAVIRIDAE; VIRUSES;

COWPEA MOSAIC VIRUS; FLOCK HOUSE VIRUS;

EID: 58349106440     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-69379-6_5     Document Type: Review

References (83)

1. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283
2. Brennan FR, Jones TD, Hamilton WD (2001) Cowpea mosaic virus as a vaccine carrier of heterologous antigens. Mol Biotechnol 17:15-26
3. Brumfield S, Willits D, Tang L, Johnson JE, Douglas T, Young M (2004) Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J Gen Virol 85:1049-1053
4. Buratti E, Tisminetzky SG, Scodeller ES, Baralle FE (1996) Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein. J Immunol Methods 197:7-18
5. Buratti E, Di Michele M, Song P, Monti-Bragadin C, Scodeller EA, Baralle FE, Tisminetzky SG (1997) Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen-presenting system. Clin Diagn Lab Immunol 4:117-121
6. Buratti E, McLain L, Tisminetzky S, Cleveland SM, Dimmock NJ, Baralle FE (1998) The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 79:2709-2716
7. Canizares MC, Lomonossoff GP, Nicholson L (2005) Development of cowpea mosaic virus-based vectors for the production of vaccines in plants. Expert Rev Vaccines 4:687-697
8. Chao JA, Lee JH, Chapados BR, Debler EW, Schneemann A, Williamson JR (2005) Dual modes of RNA-silencing suppression by Flock House virus protein B2. Nat Struct Mol Biol 12:952-957
9. Chatterji A, Burns LL, Taylor SS, Lomonossoff G, Johnson JE, Lin T, Porta C (2002) Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Intervirology 45:362-370
10. Chatterji A, Ochoa W, Paine M, Ratna BR, Johnson JE, Lin T (2004a) New addresses on an addressable virus nanoblock: uniquely reactive lys residues on cowpea mosaic virus. Chem Biol 11:855-863
11. Chatterji A, Ochoa W, Shamieh L, Salakian SP, Wong SM, Clingon G, Ghosh P, Lint T, Johnson J (2004b) Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 15:807-813
12. Da Silva DM, Schiller JT, Kast M (2003) Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21:3219-3227
13. Dalsgaard K, Uttenthal A, Jones TD, Xu F, Merryweather A, Hamilton W, Langeveld J, Boshuizen R, Kamstrup S, Lomonossoff G, Porta C, Vela C, Casal J, Meloen R, Rodgers P (1997) Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol 15:248-252
14. Dasgupta R, Ghosh A, Dasmahapatra B, Guarino LA, Kaesberg P (1984) Primary and secondary structure of black beetle virus RNA2, the genomic messenger for BBV coat protein precursor. Nucleic Acids Res 12:7215-7223
15. Destito G Yeh R, Rae CS, Finn MG, Manchester M (2007) Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 14:1152-1162
16. Douglas T, Young MJ (1998) Host-guest encapsulation of materials by assembled virus protein cages. Nature 393:152-155
17. Douglas T, Young M (1999) Virus particles as templates for materials synthesis. Adv Mater 11:679-681
18. Durrani Z, McInerney TL, McLain L, Jones T, Bellaby T, Brennan FR, Dimmock NJ (1998) Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Meth 220:93-103
19. Engler H, Machemer T, Philopena J, Wen SF, Quijano E, Ramachandra M, Tsai V, Ralston R (2004) Acute hepatoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328:52-61
20. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161-171
21. Flenniken ML, Willits D, Harmsen AL, Liepold LO, Harmsen AJ, Young MJ, Douglas T (2006) Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol 13:161-170
22. Friesen PD, Rueckert RR (1981) Synthesis of black beetle virus proteins in cultured Drosophila cells: differential expression of RNAs 1 and 2. J Virol 37:876-886
23. Friesen PD, Rueckert RR (1982) Black beetle virus: messenger for protein B is a subgenomic viral RNA. J Virol 42:986-995
24. Gallagher T, Rueckert RR (1988) Assembly-dependent maturation cleavage in provirions of a small icosahedral insect ribovirus. J Virol 62:3399-3406
25. Gilleland HE, Gilleland LB, Staczek J, Harty RN, Garcia-Sastre A, Palese P, Brennan FR, Hamilton WD, Bendahmane M, Beachy RN (2000) Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. FEMS Immunol Med Microbiol 27:291-297
26. Goldenberg DM (1992) Cancer imaging with CEA antibodies: historical and current perspectives. Int J Biol Markers 7:183-188
27. Gordon EA, Kohout TA, Fishman PH (1990) Characterization of functional neuropeptide-Y receptors in a neuroblastoma cell-line. J Neurochemistry 55:506-513
28. Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R, Bormer O, Buchegger F, Mach JP, Burtin P et al (1989) Antigenic sites in carcinoembryonic antigen. Cancer Res 49:4852-4858
29. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491-2499
30. Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Ann Rev Immunol 19:47
31. Hooker JM, Kovacs EW, Francis MB (2004) Interior surface modification of bacteriophage MS2. J Am Chem Soc 126:3718-3719
32. Johnson J, Lin T, Lomonossoff G (1997) Presentation of heterologous peptides on plant viruses: genetics, structure, and function. Annu Rev Phytopathol 35:67-86
33. Khor IW, Lin T, Langedijk JP, Johnson JE, Manchester M (2002) Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. J Virol 76:4412-4419
34. Kickhoefer VA, Garcia Y, Mikyas Y, Johansson E, Zhou JC, Raval-Fernandes S, Minoofar P, Zink JI, Dunn B, Stewart PL, Rome LH (2005) Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc Natl Acad Sci U S A 102:4348-4352
35. Klem MT, Willits D, Young M, Douglas T (2003) 2-D array formation of genetically engineered viral cages on au surfaces and imaging by atomic force microscopy. J Am Chem Soc 125:10806-10807
36. Koudelka K, Rae CS, Gonzalez MJ, Manchester M (2007) Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus. J Virol 81:1632-1640
37. Krishna NK, Schneemann A (1999) Formation of an RNA heterodimer upon heating of nodavirus particles. J Virol 73:1699-1703
38. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlested C (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 267:10935-10938
39. Lee SW, Mao C, Flynn CE, Belcher AM (2002) Ordering of quantum dots using genetically engineered viruses. Science 296:892-895
40. Levy LS, Yudhisthira A, Kim K-S, Bergey EJ; Prasad Paras N (2002) Nanochemistry: synthesis and characterization of multifunctional nanoclinics for biological applications. Chem Mater 14:3715-3721
41. Lewis JD, Destito G, Zjilstra A, Gonzalez MJ, Quigley J, Manchester M, Stuhlmann H (2006) Viral nanoparticles (VNPs) as tools for intravital vascular imaging. Nat Med 12:354-360
42. Li H, Li WX, Ding SW (2002) Induction and suppression of RNA silencing by an animal virus. Science 296:1319-1321
43. Lin T, Chen Z, Usha R, Stauffacher C, Dai J, Schmidt T, Johnson JE (1999) The refined crystal structure of cowpea mosaic virus at 2.8 A resolution. Virology 265:20-34
44. Liu L, Canizares MC, Monger W, Perrin Y, Tsakiris E, Porta C, Shariat N, Nicholson L, Lomonossoff GP (2005) Cowpea mosaic virus-based systems for the production of antigens and antibodies in plants. Vaccine 23:1788-1792
45. Lomonossoff G, Johnson J (1991) The synthesis and structure of comovirus capsids. Program Biophys Molec Biol 55:107-137
46. Lomonossoff G, Rohll J, Spall V, Maule A, Loveland J, Porta C, Usha R, Johnson J (1993) Insertion of foreign antigenic sites into the plant virus cowpea mosaic virus protein engineering. II. In: Goodenough P (ed) Proceedings of the Second AFRC Protein Engineering Conference. 1CPL Press, Newbury, UK, pp 30-138
47. Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marlett JM, Rainey GJ, Pique ME, Scobie HM, Yeager M, Young JA, Manchester M, Schneemann A (2007) A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 3:1422-1431
48. Mandl S, Hix L, Andino R (2001) Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. J Virol 75:622-627
49. Mao C, Flynn CE, Hayhurst A, Sweeney RY, Qi J, Georgiou G, Iverson B, Belcher AM (2003) Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci U S A 100:6946-6951
50. Mao C, Solis DJ, Reiss BD, Kottmann ST, Sweeney RY, Hayhurst A, Georgiou G, Iverson B, Belcher AM (2004) Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science 303:213-217
51. Martinez X, Regner M, Kovarik J, Zarei S, Hauser C, Lambert PH, Leclerc C, Siegrist CA (2003) CD4-independent protective cytotoxic T cells induced in early life by a non-replicative delivery system based on virus-like particles. Virology 305:428-435
52. Mechtcheriakova IA, Eldarov MA, Nicholson L, Shanks M, Skryabin KG, Lomonossoff GP (2005) The use of viral vectors to produce hepatitis B virus core particles in plants. J Virol Methods 131:10-15
53. Michel MC, Beck-Sickinger AG, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150
54. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA (2004) Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 51:480-486
55. Phelps JP, Dang N, Rasochova L (2007) Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J Virol Methods 141:146-153
56. Porta C, Spall VE, Lin T, Johnson JE, Lomonossoff GP (1996) The development of cowpea mosaic virus as a potential source of novel vaccines. Intervirology 39:79-84
57. Portney NG, Singh K, Chaudhary SK, Stephens J, Destito G, Schneemann A, Manchester M, Ozkan M (2005) Organic and Inorganic nanoparticle hybrids. Langmuir 21:2098-2103
58. Prasuhn DE Jr, Singh P, Strable E, Brown S, Manchester M, Finn MG (2008) Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc 130:1328-1334
59. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR Jr (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310-1316
60. Rae CS, Wei Khor I, Wang Q, Destito G, Gonzalez MJ, Singh P, Thomas DM, Estrada MN, Powell E, Finn MG, Manchester M (2005) Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343:224-235
61. Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG (2003) Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4:472-476
62. Rennermalm A, Li YH, Bohaufs L, Jarstrand C, Brauner A, Brennan FR, Flock JI (2001) Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19:3376-3383
63. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF (2005) Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79:717-724
64. Schiappacassi M, Buratti E, D'Agaro P, Ciani L, Scodeller ES, Tisminetzky SG, Baralle FE (1997) V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system. J Virol Methods 63:121-127
65. Schneemann A, Zhong W, Gallagher TM, Rueckert RR (1992) Maturation cleavage required for infectivity of a nodavirus. J Virol. 66:6728-6734
66. Scodeller EA, Tisminetzky SG, Porro F, Schiappacassi M, De Rossi A, Chiecco-Bianchi L, Baralle FE (1995) A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. Vaccine 13:1233-1239
67. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicating exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A 94:7503-7508
68. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG (2005a) Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem 16:1572-1579
69. Sen Gupta S, Raja KS, Kaltgrad E, Strable E, Finn MG (2005b) Virus-glycopolymer conjugates by copper(I) catalysis of atom transfer radical polymerization and azide-alkyne cycloaddition. Chem Commun (Camb) 4315-4317
70. Singh P, Gonzalez MJ, Manchester M (2005) Viruses and their uses in nanotechnology. Drug Dev Res 343:224-235
71. Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, Finn MG, Manchester M (2007) Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 120:41-50
72. Soll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG (2001) Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 268:2828-2837
73. Strable E, Johnson JE, Finn MG (2004) Natural nanochemical building blocks: Icosahedral virus particles organized by attached oligonucleotides. NanoLetters 4:1385-1389
74. Taylor K, Lin T, Porta C, Mosser A, Giesing H, Lomonossoff G, Johnson J (2000) Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus. J Mol Recognit 13:71-82
75. Thiery R, Cozien J, Cabon J, Lamour F, Baud M, Schneemann A (2006) Induction of a protective immune response against viral nervous necrosis in the European sea bass Dicentrarchus labrax by using betanodavirus virus-like particles. J Virol 80:10201-1027
76. Wang Q, Kaltgrad E, Lin T, Johnson J, Finn M (2002a) Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol 9:805-811
77. Wang Q, Lin T, Johnson J, Finn M (2002b) Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem Biol 9:813-819
78. Wang Q, Lin T, Tang L, Johnson J, Finn M (2002c) Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed 41:459-462
79. Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG (2003) Bioconjugation by copper(I)-catalyzed azide-alkyne [3+2] cycloaddition. J Am Chem Soc 125:3192-3193
80. Yasawardene SG, Lomonossoff GP, Ramasamy R (2003) Expression, immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus. Indian J Med Res 118:115-124
81. Yewdell J, Anton LC, Bacik I, Schubert U, Snyder HL, Bennink JR (1999a) Generating MHC class I ligands from viral gene products. Immunol Rev 172:97-108
82. Yewdell JW, Norbury CC, Bennink JR (1999b) Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8 T-cell responses to infectious agents, tumors, transplants and vaccines. Adv Immunol 73:1-77
83. Zinkernagel R (2002) On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 32:2385-2392